It has been a rocky week for healthcare after the NIH stopped a major alcohol consumption study due to concerns of fraud, Theranos’ Elizabeth Holmes was indicted on wire fraud charges and Purdue Pharma’s entire salesforce was laid off. Reuters warned that the costs of antibiotic resistance could reach up to US$100 trillion by 2050. In Mexico, the CCE called for a reform to the healthcare system to ensure coverage.
In more positive news, Roche invests in genetic tests and Sanofi in immuno-oncology. In local news, CIMAV’s researchers reported their advances on the creation of an electronic nose that can detect diabetes. Also, Mexico Health Review spoke to Manuel Escobedo, President of AMIS, on the challenges and opportunities insurance companies have in Mexico.
The country is also seeing a new insurance trend, InsurTech, which is a disruptive technology that aims to provide insurance products that large insurers cannot cover.
Now, jump into last week’s highlights:
Mexican researchers are looking to create an electronic nose that can “smell” diabetes.
The Business Coordination Council (CCE) added its voice to those calling for a reform of the healthcare system and warned that otherwise it may not be possible to address future healthcare needs.
Antibiotic resistance is expected to cost the world US$100 trillion by 2050: Reuters.
The National Institutes of Health (NIH) stopped a study linking alcohol consumption with reduced cardiovascular diseases after the organization discovered that researchers had manipulated its research plan to produce a positive outcome for its sponsors, which included five breweries.
Purdue Pharma, manufacturer of top-seller and highly addictive painkiller OxiContin and perceived culprit of the US’s opioid addiction crisis, lays of its entire salesforce.
Roche raises bet in personalized medicine by investing US$2.4 billion in Foundation Medicine, which develops genomic tests to profile types of cancer.
Elizabeth Holmes, Founder and CEO of Theranos, has been indicted for wire fraud and conspiracy to commit wire fraud. Theranos, once a Silicon Valley darling valued at US$9 billion, promised technology to perform hundreds of blood tests with just one drop of blood. The company became notorious after it was discovered that Holmes had lied about the capabilities of the technology she developed and that she had knowingly misled investors and patients.
Sanofi strengthened its immune-oncology pipeline with 10 products as the pharmaceutical tries to catch up and get a slice of this US$100 billion market.